COBRA Classic | COBRA Slim | COBRA Avant-Garde | |
---|---|---|---|
Number of patients | 98 | 98 | 94 |
Age (years) | 53.2±11.9 | 51.8±13.1 | 51.2±12.8 |
BMI (kg/m2) | 26.0.99±4.3 | 26.8±4.2 | 26.5±4.2 |
Gender (women) | 65.3% | 64.3% | 69.1% |
Smoking status (ever) | 57.1% | 59.2% | 60.6% |
Alcohol intake (yes) | 55.1% | 56.1% | 54.3% |
Symptom duration (weeks) | 33.8±35.5 | 33.2±38.2 | 44.2±65.6 |
Disease duration (weeks) | 1.8±3.1 | 2.6±3.3 | 3.1±6.3 |
Employed before symptom onset (yes) | 52.0% | 65.3% | 62.8% |
Employed at screening (yes) | 44.9% | 53.1% | 51.1% |
Comorbidities at screening (yes) | 72.4% | 74.5% | 64.9% |
Nocturnal pain (yes) | 69.4% | 72.4% | 68.1% |
Morning stiffness (yes) | 74.5% | 68.4% | 58.4% |
RF (yes) | 79.6% | 83.7% | 75.5% |
ACPA (yes) | 77.6% | 79.6% | 77.7% |
Erosions (yes) | 32.7% | 32.7% | 34.0% |
Total TJC | 14.7±9.5 | 13.7±8.2 | 14.0±9.0 |
Total SJC | 11.9±8.9 | 10.8±6.5 | 10.5±6.8 |
TJC28 | 9.5±6.0 | 8.5±5.5 | 8.2±5.5 |
SJC28 | 7.9±6.0 | 7.1±4.6 | 7.0±5.1 |
PGA (0–100) | 59.5±21.7 | 56.2±21.7 | 54.5±24.3 |
Pain (0–100) | 59.5±23.6 | 56.5±21.9 | 56.9±23.88 |
Fatigue (0–100) | 50.6±26.0 | 49.0±21.3 | 48.68±23.78 |
PhGA (0–100) | 54.7±18.5 | 53.1±18.1 | 51.8±18.2 |
ESR | 33.59±25.2 | 32.1±23.3 | 25.18±17.7 |
CRP | 19.7±28.9 | 21.5±33.3 | 15.1±20.0 |
DAS28(ESR) | 5.4±1.3 | 5.2±1.2 | 5.0±1.3 |
DAS28(CRP) | 5.0±1.2 | 4.9±1.1 | 4.7±1.2 |
HAQ (0–3) | 1.2±0.7 | 0.98±0.69 | 0.99±0.64 |
ACPA, anticitrullinated protein antibody; BMI, body mass index; CRP, C-reactive protein; DAS28, 28 joint disease activity score; Disease duration, time elapsed between diagnosis of RA and start of treatment; ESR, erythrocyte sedimentation rate; HAQ, health assessment questionnaire; Morning stiffness, being stiff in the morning for at least 45 min; PGA, patient global assessment; PhGA, physician global assessment; RF, rheumatoid factor; SJC, swollen joint count; Symptom duration, time elapsed between onset of symptoms and start of treatment; TJC, tender joint count; COBRA, combination therapy for early rheumatoid arthritis.
Data are presented as mean±SD or as percentages.